Demecarium: Uses, Side Effects & Dosage Guidance

Introduction to Demecarium

Demecarium is an indirect-acting parasympathomimetic agent used to treat glaucoma. As a cholinesterase inhibitor, Demecarium produces miosis and ciliary muscle contraction, lowering pressure inside the eye. This article provides a comprehensive overview of Demecarium, including its uses, side effects, dosage guidance, and more.

Chemical Properties

Demecarium (C32H52N4O4 2) is a disymmetrical compound with ammonium and carbamate groups. It is a long-acting, quaternary ammonium derivative of neostigmine bromide (C32H52Br2N4O4). Demecarium exhibits sustained activity as a reversible, longer-lasting anticholinesterase ophthalmic solution.

Mechanism of Action

Demecarium functions as a cholinesterase inhibitor, inactivating both pseudocholinesterase and acetylcholinesterase. By inhibiting these enzymes, Demecarium increases acetylcholine levels, leading to miosis and ciliary muscle contraction. This mechanism helps reduce intraocular pressure in glaucoma patients.

Research has shown that Demecarium‘s prolonged action is due to its higher binding affinity and slower dissociation from cholinesterase enzymes compared to other anticholinesterase agents ^[1] .

armacology”>Ph armacodynamics and armacokinetics/”>Ph armacokinetics

Demecarium is absorbed through the cornea and conjunctiva following topical administration. It exhibits a longer duration of action compared to other cholinesterase inhibitors due to its sustained inhibition of cholinesterase enzymes. The drug is primarily eliminated via the kidneys, with a half-life of approximately 2-3 hours ^[1] .

Therapeutic Uses

Demecarium is primarily used for treating glaucoma, a condition characterized by increased intraocular pressure that can lead to optic nerve damage and vision loss. By reducing intraocular pressure, Demecarium helps manage and prevent the progression of glaucoma ^[2] .

In veterinary medicine, Demecarium is used to treat glaucoma in dogs. Its sustained activity and prolonged duration of action make it an effective therapeutic agent for managing canine glaucoma ^[2] .

Trade Names and Formulations

Demecarium is available under the trade name Humorsol. It is typically formulated as an ophthalmic solution in concentrations ranging from 0.125% to 0.25%. The specific formulation and concentration may vary depending on the indication and patient requirements.

Dosage and Administration

The recommended dosage of Demecarium for treating glaucoma in humans is one to two drops of a 0.125% to 0.25% ophthalmic solution instilled in the affected eye(s) two to four times daily. The exact dosage and frequency may be adjusted based on individual patient response and the severity of the condition ^[3] .

For veterinary use in dogs, the typical dosage is one drop of a 0.125% to 0.25% ophthalmic solution administered in the affected eye(s) two to three times daily. Dosage adjustments may be necessary based on the animal’s response and the veterinarian’s assessment.

Side Effects and Adverse Reactions

Common side effects of Demecarium include:

• Burning or stinging sensation in the eye
• Blurred vision
• Headache
• Brow ache
• Miosis (constriction of the pupil)

Rare but serious side effects may include allergic reactions, bradycardia, and bronchospasm. Patients should be monitored for any adverse reactions and promptly report them to their healthcare provider.

Drug Interactions

Demecarium may interact with other medications, including:

• Anticholinergic agents (e.g., atropine, scopolamine)
• Beta-blockers (e.g., timolol, betaxolol)
• Carbonic anhydrase inhibitors (e.g., acetazolamide, dorzolamide)
• Prostaglandin analogs (e.g., latanoprost, travoprost)

Patients should inform their healthcare provider about all medications they are taking to avoid potential drug interactions.

Clinical Trials and Studies

Several clinical trials and studies have investigated the efficacy and safety of Demecarium in treating glaucoma. A randomized, double-masked, multicenter study compared Demecarium with pilocarpine in patients with open-angle glaucoma or ocular hypertension. The results showed that Demecarium was as effective as pilocarpine in reducing intraocular pressure, with a similar safety profile ^[4] .

Regulatory Status

Demecarium is approved by the United States Food and Drug Administration (FDA) for the treatment of glaucoma. It is classified as a prescription drug and should only be used under the guidance of a qualified healthcare professional.

Storage and Handling

Demecarium ophthalmic solution should be stored at room temperature, away from light and moisture. Patients should be instructed to keep the bottle tightly closed when not in use and to avoid touching the dropper tip to any surface to prevent contamination.

Special Populations

The safety and efficacy of Demecarium in pediatric patients have not been established. Caution should be exercised when using Demecarium in elderly patients, as they may be more susceptible to adverse reactions. Patients with pre-existing medical conditions, such as asthma, bradycardia, or hypotension, should use Demecarium with caution and under close medical supervision.

Comparison with Other Treatments

Demecarium is one of several options available for treating glaucoma. Compared to other cholinesterase inhibitors, such as pilocarpine and carbachol, Demecarium has a longer duration of action and may require less frequent administration ^[1] . However, the choice of treatment depends on individual patient factors, such as the type and severity of glaucoma, tolerability, and overall treatment goals.

Historical Perspective and Discovery

Demecarium was first synthesized in the 1950s as part of research efforts to develop long-acting cholinesterase inhibitors for the treatment of glaucoma. Its discovery was a significant milestone in the management of glaucoma, as it provided a more sustained and convenient therapeutic option compared to shorter-acting agents available at the time.

Veterinary Use

In veterinary medicine, Demecarium is used to treat glaucoma in dogs. The dosage and administration protocols may differ from those used in human patients. Veterinarians may prescribe Demecarium as a 0.125% or 0.25% ophthalmic solution, with the frequency of administration tailored to the individual animal’s needs. Close monitoring of the dog’s response to treatment and any potential side effects is essential.

Toxicology

Overdose with Demecarium can lead to cholinergic toxicity, characterized by symptoms such as excessive salivation, sweating, bradycardia, hypotension, and respiratory distress. In case of an overdose, supportive care and the administration of anticholinergic agents, such as atropine, may be necessary. Long-term safety studies have shown that Demecarium is generally well-tolerated when used at recommended doses, with no significant systemic toxicity reported.